Jan 9 (Reuters) – Clinical biopharmaceutical company Eikon Therapeutics on Friday revealed wider nine-month losses in its filing for an initial public offering in the United States. The company disclosed a net loss attributable to common stockholders of about $254 million for the nine months ended September 30, compared with a loss about $179 million […]
Health
Biopharmaceutical firm Eikon Therapeutics discloses wider loss in US IPO paperwork
Audio By Carbonatix
Jan 9 (Reuters) – Clinical biopharmaceutical company Eikon Therapeutics on Friday revealed wider nine-month losses in its filing for an initial public offering in the United States.
The company disclosed a net loss attributable to common stockholders of about $254 million for the nine months ended September 30, compared with a loss about $179 million a year earlier.
IPOs are likely to gain momentum in 2026 as anticipated interest rate cuts bolster investor confidence and appetite for risk, encouraging late-stage drugmakers to test public markets after the holiday season.
Earlier on Friday another biopharmaceutical company, Veradermics, also filed for a U.S. IPO.
Eikon Therapeutics will list on the Nasdaq under the symbol “EIKN”.
It is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.
J.P. Morgan, Morgan Stanley and BofA Securities are the underwriters for the offering.
(Reporting by Prakhar Srivastava in Bengaluru; Editing by Alan Barona)